Tokyo, May 27 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061687) titled 'Optimization of Adjuvant Osimertinib for EGFR Mutant Stage II-III Non Squamous Non Small Cell Lung Cancer (A randomized phase III study)' on May 26.
Study Type:
Interventional
Study Design:
Basic Design - Parallel
Randomization - Randomized
Blinding - Open -no one is blinded
Control - Dose comparison
Primary Sponsor:
Institute - Public Health Research Foundation
Condition:
Condition - EGFR Mutant Stage II-III Non Squamous Non Small Cell Lung Cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The aim of the study is to evaluate the non-inferiority of 40 mg/...